Skip to content
10-K

Annual Report

Oric Pharmaceuticals, Inc. ORIC

0000950170-25-022273

← back to feed
Filed
Feb 18, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 4, 2025 71.03M sh
Shares Diluted FY 2024 · Dec 31, 2023 51.45M sh
Capex FY 2024 · Dec 31, 2023 $849K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$85.69M
Cash And Equivalents FY 2024 · Dec 31, 2023 $23.38M
Current Liabilities FY 2024 · Dec 31, 2023 $20.46M
Total Liabilities FY 2024 · Dec 31, 2023 $27.92M
Current Assets FY 2024 · Dec 31, 2023 $212.6M
Total Assets FY 2024 · Dec 31, 2023 $252.01M
Eps Diluted FY 2024 · Dec 31, 2023 −$1.96
Eps Basic FY 2024 · Dec 31, 2023 −$1.96
Sga Expense FY 2024 · Dec 31, 2023 $25.61M
Net Income FY 2024 · Dec 31, 2023 −$100.7M
Operating Income FY 2024 · Dec 31, 2023 −$110.78M
Stockholders Equity FY 2024 · Dec 31, 2022 $222.35M